IL15 and neuroblastoma: Based on these studies, the safety and efficacy of GD2-CAR NKT cells co-expressing IL-15 is currently being evaluated in pediatric patients with neuroblastoma (Table 1), and an interim analysis of the first three patients found that infusion of CAR.IL15 NKT cells is safe and associated with clinical benefit (92).